Gemcitabine vs Gemcitabine (FF-10832)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ribonucleotide reductase / DNA polymerase (dCTP competition) · full Non-Small Cell Lung Cancer pipeline
Gemcitabine
Rights held by Eli Lilly; US product discontinued
NCT00003589 · Phase 3 · completed
This Phase 3 trial randomly assigned 450 people with advanced lung cancer to one of three chemotherapy combinations: paclitaxel with cisplatin, gemcitabine with cisplatin, or paclitaxel with gemcitabine. The registry does not say whether or how treatment assignment was masked. Median overall survival was 8.9 months on gemcitabine with cisplatin, 8.1 months on paclitaxel with cisplatin and 6.7 months on paclitaxel with gemcitabine, with response rates of 36.6%, 31.8% and 27.7%. The published report gives these figures without a statistical comparison between the arms, so no combination can be called the winner on this evidence.
Next expected readout: December 2026 · NCT02889666 (registry estimate)
Reported efficacy
Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively (unclear)
Result source: NCT00003589
Gemcitabine (FF-10832)
Developed by Fujifilm Pharmaceuticals U.S.A., Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2029 · NCT05318573 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Gemcitabine | Gemcitabine (FF-10832) |
|---|---|---|
| PFS, median | 5.1 vs 5.5vs ChemotherapyNCT0247782621 other results
| —Not reported |
| OS, median | 85.8NCT0032480526 other results
| —Not reported |
| ORR | 36.4% vs 29.7%vs ChemotherapyNCT0247782617 other results
| —Not reported |
| Duration of response, median | 5.5 vs 4.5vs Pem + Carb or CisNCT011607447 other results
| —Not reported |
PFS, median
- Gemcitabine
- 5.1 vs 5.5vs ChemotherapyNCT02477826
21 other results
- 4.2 vs 5.5 NCT02477826
- 4.9 vs 5.5 NCT02477826
- 5.5 vs 5.5 NCT02477826
- 8.3 vs 5.5 NCT02477826
- 5.8 vs 5.5 NCT02477826
- 9.7 vs 4.2 NCT01404260
- 5.7 vs 5.5 NCT00981058
- 7.2 vs 5.6 NCT01160744
- 5.6 vs 5.6 NCT01160744
- 6.2 vs 5 NCT00842712
- 5.6 vs 5 NCT00842712
- 6.0 vs 5.5 NCT00753714
- 8.5 NCT00655850
- 5.6 vs 5.3 NCT00842712
- 3.3 vs 3.1 NCT01951157
- 5.6 vs 5.3 NCT00842712
- 5.6 vs 4.2 NCT00870870
- 5.6 NCT01788566
- 4.3 NCT01077713
- 6.8 NCT01077713
- 6.2 NCT00735904
- Gemcitabine (FF-10832)
- —Not reported
OS, median
- Gemcitabine
- 85.8NCT00324805
26 other results
- 17.1 vs 14.9 NCT02477826
- 15.7 vs 14.9 NCT02477826
- 17.4 vs 14.9 NCT02477826
- 15.2 vs 14.9 NCT02477826
- 18.3 vs 14.9 NCT02477826
- 11.5 vs 9.9 NCT00981058
- 21.0 vs 14.9 NCT02477826
- 9.5 NCT00828841
- 8.3 NCT00828841
- 10.6 NCT00828841
- 13.9 vs 10.4 NCT01160744
- 10.4 vs 10.4 NCT01160744
- 13.6 vs 9.7 NCT00842712
- 7.2 vs 9.4 NCT01951157
- 13.6 vs 9.7 NCT00842712
- 8.9 vs 11.5 NCT00870870
- 8.6 vs 10.0 NCT00753714
- 25.5 NCT00655850
- 11.7 NCT01788566
- 5.7 NCT01077713
- 12 NCT01077713
- 14.2 NCT00735904
- 9 NCT00701558
- 8.1 NCT00003589
- 8.9 NCT00003589
- 6.7 NCT00003589
- Gemcitabine (FF-10832)
- —Not reported
ORR
- Gemcitabine
- 36.4% vs 29.7%vs ChemotherapyNCT02477826
17 other results
- 27.5% vs 29.7% NCT02477826
- 26.2% vs 29.7% NCT02477826
- 31.2% vs 28.8% NCT00981058
- 37.9% vs 29.7% NCT02477826
- 52.3% vs 29.7% NCT02477826
- 38.1% vs 29.7% NCT02477826
- 20% vs 31% NCT00870870
- 48.1% NCT01788566
- 39.5% NCT00735904
- 15.8% NCT00701558
- 49.3% vs 38% NCT01160744
- 46.5% vs 38% NCT01160744
- 37.6% vs 29.8% NCT00842712
- 17.4% vs 9.1% NCT01951157
- 27.5% vs 29.8% NCT00842712
- 4.7% NCT01077713
- 10% NCT01077713
- Gemcitabine (FF-10832)
- —Not reported
Duration of response, median
- Gemcitabine
- 5.5 vs 4.5vs Pem + Carb or CisNCT01160744
7 other results
- 4.3 vs 4.5 NCT01160744
- 7.4 vs 7.0 NCT00753714
- 6.1 vs 1.2 NCT01951157
- 4.8 vs 4.8 NCT00870870
- 5.2 NCT01077713
- 6.0 NCT01077713
- 5.8 NCT00735904
- Gemcitabine (FF-10832)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Gemcitabine (FF-10832): no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Gemcitabine: 4 of 4 rows · Gemcitabine (FF-10832): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gemcitabine |
|---|---|
| Dropout rate | 64.2%a NCT00324805 · Phase 3 · registry result, not featured evidence · combination show 32 more results0.9%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · registry result, not featured evidence · combination 1.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 · registry result, not featured evidence 1.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · registry result, not featured evidence · combination 1.1%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · registry result, not featured evidence · combination 2.8%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · registry result, not featured evidence · combination 0.5%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · registry result, not featured evidence · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · registry result, not featured evidence · combination 12.7% NCT00981058 · Phase 3 · registry result, not featured evidence · combination 9.4% NCT00478699 · Phase 3 · registry result, not featured evidence 9.8% NCT00499109 · Phase 3 · registry result, not featured evidence 5.6%Ram + Gem + Carb or Cis (Squamous) NCT01160744 · Phase 2 · registry result, not featured evidence · combination 7.2%Ram + Pem + Carb or Cis (Non-Squam NCT01160744 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT01951157 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00655850 · Phase 2 · registry result, not featured evidence · combination 13.1% NCT01788566 · Phase 2 · registry result, not featured evidence · combination 81.8%Bevacizumab + Gemcitabine NCT01077713 · Phase 2 · registry result, not featured evidence · combination 85.7%Bevacizumab + Gemcitabine + Cispla NCT01077713 · Phase 2 · registry result, not featured evidence · combination 0%2000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 33.3%2000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 100%1000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 66.7%1000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination —Once Weekly NCT00842712 · Phase 2 · registry result, not featured evidence · combination —Twice Weekly NCT00842712 · Phase 2 · registry result, not featured evidence · combination 1.7%Paclitaxel, Carboplatin, Cetuximab NCT00828841 · Phase 2 · registry result, not featured evidence · combination 1.7%Platinum, Gemcitabine, Cetuximab ( NCT00828841 · Phase 2 · registry result, not featured evidence · combination 3.1%Platinum, Pemetrexed, Cetuximab (A NCT00828841 · Phase 2 · registry result, not featured evidence · combination 16.7%GCC Plus Cixutumumab NCT00870870 · Phase 2 · registry result, not featured evidence · combination 20%GCiC Plus Cixutumumab NCT00870870 · Phase 2 · registry result, not featured evidence · combination —ZD6474 (Gemcitabine), Vandetanib NCT00753714 · Phase 2 · registry result, not featured evidence · combination 98.4%ZD6474 (Vandetanib),Gemcitabine NCT00753714 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT00735904 · Phase 2 · registry result, not featured evidence · combination 78.9% NCT00701558 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 27%a NCT00324805 · Phase 3 · registry result, not featured evidence · combination show 32 more results0%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · registry result, not featured evidence · combination 0.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 · registry result, not featured evidence 0%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · registry result, not featured evidence · combination 0.5%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · registry result, not featured evidence · combination 0%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · registry result, not featured evidence · combination 0.3%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · registry result, not featured evidence · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · registry result, not featured evidence · combination — NCT00981058 · Phase 3 · registry result, not featured evidence · combination — NCT00478699 · Phase 3 · registry result, not featured evidence — NCT00499109 · Phase 3 · registry result, not featured evidence —Ram + Gem + Carb or Cis (Squamous) NCT01160744 · Phase 2 · registry result, not featured evidence · combination —Ram + Pem + Carb or Cis (Non-Squam NCT01160744 · Phase 2 · registry result, not featured evidence · combination — NCT01951157 · Phase 2 · registry result, not featured evidence · combination — NCT00655850 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT01788566 · Phase 2 · registry result, not featured evidence · combination 4.5%Bevacizumab + Gemcitabine NCT01077713 · Phase 2 · registry result, not featured evidence · combination 2.4%Bevacizumab + Gemcitabine + Cispla NCT01077713 · Phase 2 · registry result, not featured evidence · combination 0%2000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 0%2000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 0%1000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 33.3%1000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination —Once Weekly NCT00842712 · Phase 2 · registry result, not featured evidence · combination —Twice Weekly NCT00842712 · Phase 2 · registry result, not featured evidence · combination —Paclitaxel, Carboplatin, Cetuximab NCT00828841 · Phase 2 · registry result, not featured evidence · combination —Platinum, Gemcitabine, Cetuximab ( NCT00828841 · Phase 2 · registry result, not featured evidence · combination —Platinum, Pemetrexed, Cetuximab (A NCT00828841 · Phase 2 · registry result, not featured evidence · combination 0%GCC Plus Cixutumumab NCT00870870 · Phase 2 · registry result, not featured evidence · combination 8%GCiC Plus Cixutumumab NCT00870870 · Phase 2 · registry result, not featured evidence · combination —ZD6474 (Gemcitabine), Vandetanib NCT00753714 · Phase 2 · registry result, not featured evidence · combination 42.6%ZD6474 (Vandetanib),Gemcitabine NCT00753714 · Phase 2 · registry result, not featured evidence · combination 7.9% NCT00735904 · Phase 2 · registry result, not featured evidence · combination — NCT00701558 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 76.6%a NCT00324805 · Phase 3 · registry result, not featured evidence · combination show 32 more results27%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · registry result, not featured evidence · combination 61.1%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 · registry result, not featured evidence 70.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · registry result, not featured evidence · combination 69.2%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · registry result, not featured evidence · combination 65.1%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · registry result, not featured evidence · combination 64%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · registry result, not featured evidence · combination 61.9%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · registry result, not featured evidence · combination 48.7% NCT00981058 · Phase 3 · registry result, not featured evidence · combination — NCT00478699 · Phase 3 · registry result, not featured evidence — NCT00499109 · Phase 3 · registry result, not featured evidence 54.9%Ram + Gem + Carb or Cis (Squamous) NCT01160744 · Phase 2 · registry result, not featured evidence · combination 65.7%Ram + Pem + Carb or Cis (Non-Squam NCT01160744 · Phase 2 · registry result, not featured evidence · combination 72% NCT01951157 · Phase 2 · registry result, not featured evidence · combination 69.4% NCT00655850 · Phase 2 · registry result, not featured evidence · combination 54.1% NCT01788566 · Phase 2 · registry result, not featured evidence · combination 39.5%Bevacizumab + Gemcitabine NCT01077713 · Phase 2 · registry result, not featured evidence · combination 25%Bevacizumab + Gemcitabine + Cispla NCT01077713 · Phase 2 · registry result, not featured evidence · combination 33.3%2000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 0%2000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 0%1000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 66.7%1000 mg NCT00842712 · Phase 2 · registry result, not featured evidence · combination 49.4%Once Weekly NCT00842712 · Phase 2 · registry result, not featured evidence · combination 58%Twice Weekly NCT00842712 · Phase 2 · registry result, not featured evidence · combination 46.4%Paclitaxel, Carboplatin, Cetuximab NCT00828841 · Phase 2 · registry result, not featured evidence · combination 54.2%Platinum, Gemcitabine, Cetuximab ( NCT00828841 · Phase 2 · registry result, not featured evidence · combination 52.3%Platinum, Pemetrexed, Cetuximab (A NCT00828841 · Phase 2 · registry result, not featured evidence · combination 83.3%GCC Plus Cixutumumab NCT00870870 · Phase 2 · registry result, not featured evidence · combination 60%GCiC Plus Cixutumumab NCT00870870 · Phase 2 · registry result, not featured evidence · combination 42.6%ZD6474 (Gemcitabine), Vandetanib NCT00753714 · Phase 2 · registry result, not featured evidence · combination —ZD6474 (Vandetanib),Gemcitabine NCT00753714 · Phase 2 · registry result, not featured evidence · combination 39.5% NCT00735904 · Phase 2 · registry result, not featured evidence · combination 10.5% NCT00701558 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a creatinine increased 33.6% neutrophil count decreased 32.1% anemia 24.9% NCT00324805 · Phase 3 · registry result, not featured evidence · combination show 29 more results3 mg/kg + 1 mg/kg constipation 21.6% fatigue 21.6% nausea 21.6% NCT02998528 · Phase 3 · registry result, not featured evidence · combination decreased appetite 24.8% dyspnoea 23.8% diarrhoea 22.5% NCT02477826 · Phase 3 · registry result, not featured evidence decreased appetite 33.2% fatigue 27.4% diarrhoea 26.1% NCT02477826 · Phase 3 · registry result, not featured evidence · combination decreased appetite 33% dyspnoea 25.4% diarrhoea 23.8% NCT02477826 · Phase 3 · registry result, not featured evidence · combination anaemia 46.5% nausea 45.9% constipation 36.6% NCT02477826 · Phase 3 · registry result, not featured evidence · combination anaemia 46.4% nausea 33.6% decreased appetite 28% NCT02477826 · Phase 3 · registry result, not featured evidence · combination anaemia 50% hyponatraemia 37.3% aspartate aminotransferase increased 36.5% NCT02477826 · Phase 3 · registry result, not featured evidence · combination nausea 49.3% rash 46.8% anaemia 41.1% NCT00981058 · Phase 3 · registry result, not featured evidence · combination neutropenia 73.2% fatigue 54.9% anaemia 53.5% NCT01160744 · Phase 2 · registry result, not featured evidence · combination fatigue 65.7% nausea 52.2% anaemia 47.8% NCT01160744 · Phase 2 · registry result, not featured evidence · combination asthenia/fatigue 68% anaemia 60% nausea 52% NCT01951157 · Phase 2 · registry result, not featured evidence · combination fatigue: induction 88.9% hypertension grade: end of induction 88.9% anemia: induction 75% NCT00655850 · Phase 2 · registry result, not featured evidence · combination nausea 73.8% decreased appetite 57.4% rash 45.9% NCT01788566 · Phase 2 · registry result, not featured evidence · combination neutropenia 27.9% hypertension 25.6% asthenia 20.9% NCT01077713 · Phase 2 · registry result, not featured evidence · combination neutropenia 57.5% nausea 42.5% thrombocytopenia 40% NCT01077713 · Phase 2 · registry result, not featured evidence · combination 2000 mg rash 100% alopecia 66.7% diarrhoea 66.7% NCT00842712 · Phase 2 · registry result, not featured evidence · combination 2000 mg rash 100% leukopenia 66.7% anorexia 33.3% NCT00842712 · Phase 2 · registry result, not featured evidence · combination 1000 mg epistaxis 100% fatigue 100% rash 100% NCT00842712 · Phase 2 · registry result, not featured evidence · combination 1000 mg anorexia 100% fatigue 100% haemoglobin decreased 100% NCT00842712 · Phase 2 · registry result, not featured evidence · combination Once Weekly nausea 57.6% neutropenia 49.4% rash 41.2% NCT00842712 · Phase 2 · registry result, not featured evidence · combination Twice Weekly nausea 52% anaemia 42% neutropenia 42% NCT00842712 · Phase 2 · registry result, not featured evidence · combination fatigue 55.7% weight decreased 50.6% nausea 41.7% NCT00828841 · Phase 2 · registry result, not featured evidence · combination fatigue 55.5% thrombocytopenia 51.7% anemia 44.5% NCT00828841 · Phase 2 · registry result, not featured evidence · combination fatigue 58.5% nausea 46.9% weight decreased 43.1% NCT00828841 · Phase 2 · registry result, not featured evidence · combination dermatitis acneiform 83.3% fatigue 66.7% neutropenia 66.7% NCT00870870 · Phase 2 · registry result, not featured evidence · combination thrombocytopenia 76% constipation 68% fatigue 68% NCT00870870 · Phase 2 · registry result, not featured evidence · combination pyrexia 27.9% rash 24.6% fatigue 23% NCT00753714 · Phase 2 · registry result, not featured evidence · combination nausea 42.1% anaemia 28.9% vomiting 28.9% NCT00735904 · Phase 2 · registry result, not featured evidence · combination anaemia of malignant disease 36.8% thrombocytopenia 31.6% rash 15.8% NCT00701558 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Gemcitabine
show 14 more results
show 1 more result
show 16 more results
show 12 more results
show 5 more results
+ 27 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gemcitabine's landscape · Gemcitabine (FF-10832)'s landscape